Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

Fnu Aakash¹, Savanah D Gisriel², Amer M Zeidan³, John M Bennett⁴, Rafael Bejar⁵, Jan Philipp Bewersdorf⁶, Uma M Borate⁷, Jacqueline Boultwood⁸, Andrew M Brunner⁹, Rena Buckstein¹⁰, Hetty E Carraway¹¹, Jane E Churpek¹², Naval G Daver¹³, Amy E DeZern¹⁴, Fabio Efficace¹⁵, Pierre Fenaux¹⁶, Maria E Figueroa¹⁷, Guillermo Garcia-Manero¹³, Steven D Gore¹⁸, Peter L Greenberg¹⁹, Elizabeth A Griffiths²⁰, Stephanie Halene³, Christopher S Hourigan²¹, Tae Kon Kim²², Nina Kim²³, Rami S Komrokji²⁴, Vijay K Kutchroo²⁵, Alan F List²⁶, Richard F Little¹⁸, Ravindra Majeti¹⁹, Aziz Nazha²⁷, Stephen D Nimer²⁸, Olatoyosi Odenike²⁹, Eric Padron²⁴, Mrinal M Patnaik³⁰, Uwe Platzbecker³¹, Matteo G Della Porta³², Gail J Roboz³³, David A Sallman²⁴, Valeria Santini³⁴, Guillermo Sanz³⁵, Michael R Savona²², Mikkael A Sekeres²⁸, Maximilian Stahl³⁶, Daniel T Starczynowski³⁷, David P Steensma³⁸, Justin Taylor²⁸, Omar Abdel-Wahab⁶, Andrew H Wei³⁹, Zhuoer Xie²⁴, Mina L Xu⁴⁰, Robert P Hasserjian⁴¹, Sanam Loghavi⁴²

Affiliations

¹ Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Pathology, University of Texas Medical Branch, Galveston, Texas.
² Department of Pathology, Yale University School of Medicine, New Haven, Connecticut; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
³ Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut.
⁴ James P. Wilmot Cancer Center, Division of Hematopathology, University of Rochester Medical Center, Rochester, New York.
⁵ Division of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, California.
⁶ Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York.
⁷ Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
⁸ Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
⁹ Division of Hematology, Massachusetts General Hospital Brigham, Boston, Massachusetts.
¹⁰ Division of Medical Oncology/Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
¹¹ Leukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
¹² Division of Haematology, Oncology, and Palliative Care, Department of Medicine, Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
¹³ Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
¹⁴ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland.
¹⁵ Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy.
¹⁶ Service d'hématologie, Hôpital Saint-Louis (Assistance Publique Hôpitaux de Paris), Université de Paris-Cité, Paris, France.
¹⁷ Biochemistry & Molecular Biology, Sylvester Comprehensive Cancer Center. University of Miami Miller School of Medicine, Miami, Florida.
¹⁸ Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland.
¹⁹ Division of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
²⁰ Roswell Park Comprehensive Cancer Center, Buffalo, New York.
²¹ Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, District of Columbia.
²² Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
²³ NCI, NIH, Bethesda, Maryland.
²⁴ Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
²⁵ Brigham and Women's Hospital, Boston, Massachusetts.
²⁶ Chief Scientific Officer, Stelexis Therapeutics, New York, New York.
²⁷ Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
²⁸ Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
²⁹ Leukemia Program, Section of Hematology/Oncology, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
³⁰ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
³¹ Department of Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
³² IRCCS Humanitas Research Hospital, Department of Biomedical Sciences, Humanitas University, Milan, Italy.
³³ Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York.
³⁴ Myelodysplastic Syndromes Unit, Department of Experimental and Clinical Medicine, Hematology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.
³⁵ Health Research Institute La Fe, Valencia, Spain; Hospital Universitario y Politécnico La Fe, Valencia, Spain; CIBERONC, IS Carlos III, Madrid, Spain.
³⁶ Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
³⁷ Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Cincinnati, Ohio.
³⁸ David Steensma LLC, Cambridge, Massachusetts.
³⁹ Department of Haematology, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Victoria, Australia.
⁴⁰ Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.
⁴¹ Department of Pathology, Massachusetts General Hospital Brigham, Boston, Massachusetts.
⁴² Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: Sloghavi@mdanderson.org.

PMID: 39322118
DOI: 10.1016/j.modpat.2024.100615

Review

Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

Fnu Aakash et al. Mod Pathol. 2024 Dec.

. 2024 Dec;37(12):100615.

doi: 10.1016/j.modpat.2024.100615. Epub 2024 Sep 23.

Authors

Affiliations

¹ Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Pathology, University of Texas Medical Branch, Galveston, Texas.
² Department of Pathology, Yale University School of Medicine, New Haven, Connecticut; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
³ Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut.
⁴ James P. Wilmot Cancer Center, Division of Hematopathology, University of Rochester Medical Center, Rochester, New York.
⁵ Division of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, California.
⁶ Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York.
⁷ Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
⁸ Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
⁹ Division of Hematology, Massachusetts General Hospital Brigham, Boston, Massachusetts.
¹⁰ Division of Medical Oncology/Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
¹¹ Leukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
¹² Division of Haematology, Oncology, and Palliative Care, Department of Medicine, Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
¹³ Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
¹⁴ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland.
¹⁵ Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy.
¹⁶ Service d'hématologie, Hôpital Saint-Louis (Assistance Publique Hôpitaux de Paris), Université de Paris-Cité, Paris, France.
¹⁷ Biochemistry & Molecular Biology, Sylvester Comprehensive Cancer Center. University of Miami Miller School of Medicine, Miami, Florida.
¹⁸ Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland.
¹⁹ Division of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
²⁰ Roswell Park Comprehensive Cancer Center, Buffalo, New York.
²¹ Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, District of Columbia.
²² Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
²³ NCI, NIH, Bethesda, Maryland.
²⁴ Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
²⁵ Brigham and Women's Hospital, Boston, Massachusetts.
²⁶ Chief Scientific Officer, Stelexis Therapeutics, New York, New York.
²⁷ Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
²⁸ Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
²⁹ Leukemia Program, Section of Hematology/Oncology, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
³⁰ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
³¹ Department of Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
³² IRCCS Humanitas Research Hospital, Department of Biomedical Sciences, Humanitas University, Milan, Italy.
³³ Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York.
³⁴ Myelodysplastic Syndromes Unit, Department of Experimental and Clinical Medicine, Hematology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.
³⁵ Health Research Institute La Fe, Valencia, Spain; Hospital Universitario y Politécnico La Fe, Valencia, Spain; CIBERONC, IS Carlos III, Madrid, Spain.
³⁶ Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
³⁷ Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Cincinnati, Ohio.
³⁸ David Steensma LLC, Cambridge, Massachusetts.
³⁹ Department of Haematology, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Victoria, Australia.
⁴⁰ Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.
⁴¹ Department of Pathology, Massachusetts General Hospital Brigham, Boston, Massachusetts.
⁴² Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: Sloghavi@mdanderson.org.

PMID: 39322118
DOI: 10.1016/j.modpat.2024.100615

Abstract

Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization Classification of Haematolymphoid tTumours and the International Consensus Classification) further subcharacterized MDS into morphologically and genetically defined groups. Accurate diagnosis and subclassification of MDS require a multistep systemic approach. The International Consortium for MDS (icMDS) summarizes a contemporary, practical, and multimodal approach to MDS diagnosis and classification.

Keywords: MDS; classification; diagnosis; icMDS; myelodysplastic neoplasms; myelodysplastic syndromes.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Grants and funding

P50 CA254838/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

Affiliations

Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous